Objective: To evaluate the efficacy of Yiqi Fumai freeze-dry powder (YFP) on ischemic diastolic heart failure. Methods: 100 patients diagnosed with unstable angina accompanying ischemic diastolic heart failure (IDHF) ...Objective: To evaluate the efficacy of Yiqi Fumai freeze-dry powder (YFP) on ischemic diastolic heart failure. Methods: 100 patients diagnosed with unstable angina accompanying ischemic diastolic heart failure (IDHF) were selected randomly. 52 patients with TCM syndrome of qi-yin deficiency were divided into Chinese and Western combination therapy group. 48 patients have no TCM syndrome of qi-yin deficiency, and were treated with standard western medicine. After treatment, Seattle Angina Questionnaire Evaluation, ECG, conventional and stress echocardiography (SE) index, NT-proBNP were compared between before and after treatment. Results: The differences of PL, TS, DP between before and after treatment by YFP were statistically significant展开更多
OBJECTIVE: To evaluate the efficacy of Tongyang Fumai decoction(通阳复脉方, TYFM) on the quality of life(QOL) as a complementary therapy for sick sinus syndrome(SSS). METHODS: This randomized controlled study involved...OBJECTIVE: To evaluate the efficacy of Tongyang Fumai decoction(通阳复脉方, TYFM) on the quality of life(QOL) as a complementary therapy for sick sinus syndrome(SSS). METHODS: This randomized controlled study involved 224 patients with symptomatic SSS. Patients were randomly assigned to either the TYFM group or the control group(receiving theophylline sustained-release tablets). The primary endpoints included changes in average heart rate, the longest R to R(RR) interval, and the occurrences of long RR intervals. Secondary endpoints comprised the Short Form(SF)-36 questionnaires, the Self-Rating Anxiety Scale(SAS), and the Self-Rating Depression Scale(SDS). RESULTS: TYFM significantly improved average heart rate(TYFM: 6 bpm vs control: 3 bpm, P < 0.01), shortened longest RR interval(TYFM:-0.20 s vs control:-0.0027 s, P < 0.05), and reduced numbers of long RR(TYFM:-99 vs control:-59, P < 0.01). In SF-36, TYFM enhanced physical and mental components(P < 0.01), outperforming the control group. TYFM also improved eight SF-36 dimensions significantly(P < 0.05 or P < 0.01). Regarding SAS and SDS, TYFM reduced scores significantly(P < 0.01), while SAS improved in the control group(P < 0.01), with no change in SDS. Statistically significant differences(P < 0.01) were observed in SAS and SDS between TYFM and control groups postintervention. CONCLUSIONS: TYFM emerges as a promising alternative strategy for treating SSS, demonstrating favorable therapeutic effects and significant improvements in the quality of life for patients with SSS.展开更多
Objective： To study the effect of the Chinese medicine Qiangxin Fumai Granule （强心复脉颗粒, QFG） on electrophysiological functions of the sinoatrial node during ischemia-reperfusion （IR） of the right coronary ar...Objective： To study the effect of the Chinese medicine Qiangxin Fumai Granule （强心复脉颗粒, QFG） on electrophysiological functions of the sinoatrial node during ischemia-reperfusion （IR） of the right coronary artery in rabbits. Methods： The right coronary artery IR model in rabbits was adopted. The modeled rabbits were randomly divided into 4 groups： the model group, the atropine group, the highdose QFG group, and the low-dose QFG group, with 8 animals in each group. In addition, twelve rabbits were selected for the sham-operative group. The drugs were administered once via duodenal perfusion after modeling had been stabilized for 10 min. The changes in AA interval, the sinoatrial conduction time （SACT）, the sinus node recovery time （SNRT）, the corrected sinus node recovery time （CSNRT） and the index of sinus node recovery time （ISNRT） at different time points during ischemia and reperfusion were measured. Results： The AA interval was prolonged for more than 40 ms in the model group during ischemia. Compared with the model group, the four electrophysiological parameters abovementioned in the high-dose QFG group and the low-dose QFG group were decreased to different extents at each time point （P〈0.01 or P〈0.05）, and no statistically significant differences were found between the QFG groups and the atropine group （P〉0.05）. Conclusion： QFG is beneficial for accelerating the recovery of sinus node autorhythmicity and conduction function, so as to protect electrophysiological functions of the sinoatrial node. Accelerating the recovery of autorhythmicity and conduction function in the sinus node is considered its electrophysiological mechanism in the treatment of sinoatrial node injury induced by ischemia.展开更多
Objective:Yiqi Fumai Lyophilized Injection(YQFM),a Chinese medicine injection,has been widely used for the treatment of cardiovascular diseases,especially heart failure(HF).However,bioactive compounds and underlying m...Objective:Yiqi Fumai Lyophilized Injection(YQFM),a Chinese medicine injection,has been widely used for the treatment of cardiovascular diseases,especially heart failure(HF).However,bioactive compounds and underlying mechanisms of YQFM in treating HF remain poorly understood.Materials and Methods:Network pharmacology was employed to investigate the bioactive compounds and mechanisms of YQFM.A compound-target network was constructed to screen bioactive compounds based on contribution index calculation.Then,an adriamycin-induced HF rat model was established to evaluate the cardio-protective effects of YQFM by hematoxylin and eosin staining and enzyme-linked immunosorbent assays.Results:Network pharmacology indicated that YQFM may alleviate HF through 36 compounds and 109 targets.Particularly,ginsenosides Rb1,Rg1,Re,Rf,Rb2,Rh1,schisandrin,and ginsenoside Rc were indicated as the top contributors of YQFM in treating HF.YQFM was predicted to act on multiple targets such as vascular endothelial growth factor A,interleukin-2(IL-2),IL-6,and IL-1β,as well as to regulate signaling pathways such as hypoxia-inducible factor 1,tumor necrosis factor,VEGF,and PI3K-Akt.The pharmacological study suggested that YQFM could attenuate cardiac injury and up-regulate plasma concentrations of VEGFR-1 and NO in HF rats.Ginsenoside Rb1,as the major contributor from network pharmacology analysis,also showed a cardioprotective effect and up-regulation of VEGFR-1 in plasma.Conclusions:Ginsenosides and schisandrin were predicted as the most important contributors to the cardioprotective effect of YQMF.Ginsenoside Rb1 was proved to alleviate HF and increase the plasma concentration of VEGFR-1.展开更多
目的探讨注射用益气复脉(冻干,YQFM)联合酒石酸美托洛尔对2型糖尿病(T2DM)合并心力衰竭(HF)患者的疗效。方法回顾性选取山西省中医院2021年6月—2023年6月收治的200例T2DM合并HF患者作为研究对象,根据治疗方案不同分为对照组和试验组,...目的探讨注射用益气复脉(冻干,YQFM)联合酒石酸美托洛尔对2型糖尿病(T2DM)合并心力衰竭(HF)患者的疗效。方法回顾性选取山西省中医院2021年6月—2023年6月收治的200例T2DM合并HF患者作为研究对象,根据治疗方案不同分为对照组和试验组,对照组采用二甲双胍常规降糖和酒石酸美托洛尔抗HF治疗,试验组在对照组的基础上加用YQFM。对比治疗前后两组患者的血糖水平、心功能指标、心肌标志物N末端B型脑钠肽前体(NT-proBNP)、6 min步行试验距离(6MWD),观察两组不良反应情况。结果治疗前,两组患者的各项基线资料比较无统计学意义。治疗后试验组总有效率(91.0%)明显高于对照组(79.0%)(P<0.05);治疗前,两组患者的血糖水平、心功能指标、心肌标志物水平、运动耐力等指标比较,差异均无统计学意义(P>0.05)。治疗后,两组患者的空腹血糖(FPG)、餐后2 h血糖(2 h PG)水平和糖化血红蛋白(HbA1c)水平均明显低于本组治疗前(P<0.05),左室射血分数(LVEF)水平均高于本组治疗前,左室舒张末期内径(LVEDd)和左室收缩末期内径(LVEDs)水平均明显低于本组治疗前(P<0.05),血清NT-proBNP水平均低于本组治疗前(P<0.05),6MWD水平明显高于本组治疗前(P<0.05)。治疗后,试验组与对照组比较,上述各项血糖指标、心功能指标、运动耐力等的改善效果均更显著(P<0.05)。治疗期间两组患者出现的不良反应有胸闷、心慌、皮疹和胃肠道轻微不适等,均未出现明显不适和过敏情况,两组不良反应总发生率比较,差异不显著(P>0.05)。结论YQFM联合酒石酸美托洛尔治疗T2DM合并HF患者能发挥协同治疗作用,可显著改善患者心功能、提高运动耐量,且安全性好。展开更多
文摘Objective: To evaluate the efficacy of Yiqi Fumai freeze-dry powder (YFP) on ischemic diastolic heart failure. Methods: 100 patients diagnosed with unstable angina accompanying ischemic diastolic heart failure (IDHF) were selected randomly. 52 patients with TCM syndrome of qi-yin deficiency were divided into Chinese and Western combination therapy group. 48 patients have no TCM syndrome of qi-yin deficiency, and were treated with standard western medicine. After treatment, Seattle Angina Questionnaire Evaluation, ECG, conventional and stress echocardiography (SE) index, NT-proBNP were compared between before and after treatment. Results: The differences of PL, TS, DP between before and after treatment by YFP were statistically significant
基金Beijing Clinical Application Research Project:Evaluation of the Therapeutic Efficacy of Tongyang Huoxue Decoction based on the Heart-Kidney Simultaneous Treatment for Sick Sinus Syndrome (No. Z181100001718184)Academic Inheritance and Communication Project of China Academy of Chinese Medical Sciences:Academic Experience Inheritance of Liu Zhiming (No. CI2022E012XB)+1 种基金High Level Chinese Medical Hospital Promotion Project:In-Hospital Pharmaceutical Preparation based on the Experience of Renowned Traditional Chinese Medicine Physicians (No. HLCMHPP2023053)the Fundamental Research Funds for the Central Public Welfare Research Institutes:Mechanism of'Kidney Tonifying,Yang Activating,Blood Circulating'Chinese Medicine in Improving Sinoatrial Node Injury Under Hypoxic Stress (No. ZZ17-XRZ-028)。
文摘OBJECTIVE: To evaluate the efficacy of Tongyang Fumai decoction(通阳复脉方, TYFM) on the quality of life(QOL) as a complementary therapy for sick sinus syndrome(SSS). METHODS: This randomized controlled study involved 224 patients with symptomatic SSS. Patients were randomly assigned to either the TYFM group or the control group(receiving theophylline sustained-release tablets). The primary endpoints included changes in average heart rate, the longest R to R(RR) interval, and the occurrences of long RR intervals. Secondary endpoints comprised the Short Form(SF)-36 questionnaires, the Self-Rating Anxiety Scale(SAS), and the Self-Rating Depression Scale(SDS). RESULTS: TYFM significantly improved average heart rate(TYFM: 6 bpm vs control: 3 bpm, P < 0.01), shortened longest RR interval(TYFM:-0.20 s vs control:-0.0027 s, P < 0.05), and reduced numbers of long RR(TYFM:-99 vs control:-59, P < 0.01). In SF-36, TYFM enhanced physical and mental components(P < 0.01), outperforming the control group. TYFM also improved eight SF-36 dimensions significantly(P < 0.05 or P < 0.01). Regarding SAS and SDS, TYFM reduced scores significantly(P < 0.01), while SAS improved in the control group(P < 0.01), with no change in SDS. Statistically significant differences(P < 0.01) were observed in SAS and SDS between TYFM and control groups postintervention. CONCLUSIONS: TYFM emerges as a promising alternative strategy for treating SSS, demonstrating favorable therapeutic effects and significant improvements in the quality of life for patients with SSS.
基金the Funds of State Administration of Traditional Chinese Medicine(No.04-05JP61)
文摘Objective： To study the effect of the Chinese medicine Qiangxin Fumai Granule （强心复脉颗粒, QFG） on electrophysiological functions of the sinoatrial node during ischemia-reperfusion （IR） of the right coronary artery in rabbits. Methods： The right coronary artery IR model in rabbits was adopted. The modeled rabbits were randomly divided into 4 groups： the model group, the atropine group, the highdose QFG group, and the low-dose QFG group, with 8 animals in each group. In addition, twelve rabbits were selected for the sham-operative group. The drugs were administered once via duodenal perfusion after modeling had been stabilized for 10 min. The changes in AA interval, the sinoatrial conduction time （SACT）, the sinus node recovery time （SNRT）, the corrected sinus node recovery time （CSNRT） and the index of sinus node recovery time （ISNRT） at different time points during ischemia and reperfusion were measured. Results： The AA interval was prolonged for more than 40 ms in the model group during ischemia. Compared with the model group, the four electrophysiological parameters abovementioned in the high-dose QFG group and the low-dose QFG group were decreased to different extents at each time point （P〈0.01 or P〈0.05）, and no statistically significant differences were found between the QFG groups and the atropine group （P〉0.05）. Conclusion： QFG is beneficial for accelerating the recovery of sinus node autorhythmicity and conduction function, so as to protect electrophysiological functions of the sinoatrial node. Accelerating the recovery of autorhythmicity and conduction function in the sinus node is considered its electrophysiological mechanism in the treatment of sinoatrial node injury induced by ischemia.
基金supported by the National Key Research and Development Program of China(No.2017YFC1700400,2017YFC1700405)the National Natural Science Foundation of China(No.81921001,82122073)。
文摘Objective:Yiqi Fumai Lyophilized Injection(YQFM),a Chinese medicine injection,has been widely used for the treatment of cardiovascular diseases,especially heart failure(HF).However,bioactive compounds and underlying mechanisms of YQFM in treating HF remain poorly understood.Materials and Methods:Network pharmacology was employed to investigate the bioactive compounds and mechanisms of YQFM.A compound-target network was constructed to screen bioactive compounds based on contribution index calculation.Then,an adriamycin-induced HF rat model was established to evaluate the cardio-protective effects of YQFM by hematoxylin and eosin staining and enzyme-linked immunosorbent assays.Results:Network pharmacology indicated that YQFM may alleviate HF through 36 compounds and 109 targets.Particularly,ginsenosides Rb1,Rg1,Re,Rf,Rb2,Rh1,schisandrin,and ginsenoside Rc were indicated as the top contributors of YQFM in treating HF.YQFM was predicted to act on multiple targets such as vascular endothelial growth factor A,interleukin-2(IL-2),IL-6,and IL-1β,as well as to regulate signaling pathways such as hypoxia-inducible factor 1,tumor necrosis factor,VEGF,and PI3K-Akt.The pharmacological study suggested that YQFM could attenuate cardiac injury and up-regulate plasma concentrations of VEGFR-1 and NO in HF rats.Ginsenoside Rb1,as the major contributor from network pharmacology analysis,also showed a cardioprotective effect and up-regulation of VEGFR-1 in plasma.Conclusions:Ginsenosides and schisandrin were predicted as the most important contributors to the cardioprotective effect of YQMF.Ginsenoside Rb1 was proved to alleviate HF and increase the plasma concentration of VEGFR-1.
文摘目的探讨注射用益气复脉(冻干,YQFM)联合酒石酸美托洛尔对2型糖尿病(T2DM)合并心力衰竭(HF)患者的疗效。方法回顾性选取山西省中医院2021年6月—2023年6月收治的200例T2DM合并HF患者作为研究对象,根据治疗方案不同分为对照组和试验组,对照组采用二甲双胍常规降糖和酒石酸美托洛尔抗HF治疗,试验组在对照组的基础上加用YQFM。对比治疗前后两组患者的血糖水平、心功能指标、心肌标志物N末端B型脑钠肽前体(NT-proBNP)、6 min步行试验距离(6MWD),观察两组不良反应情况。结果治疗前,两组患者的各项基线资料比较无统计学意义。治疗后试验组总有效率(91.0%)明显高于对照组(79.0%)(P<0.05);治疗前,两组患者的血糖水平、心功能指标、心肌标志物水平、运动耐力等指标比较,差异均无统计学意义(P>0.05)。治疗后,两组患者的空腹血糖(FPG)、餐后2 h血糖(2 h PG)水平和糖化血红蛋白(HbA1c)水平均明显低于本组治疗前(P<0.05),左室射血分数(LVEF)水平均高于本组治疗前,左室舒张末期内径(LVEDd)和左室收缩末期内径(LVEDs)水平均明显低于本组治疗前(P<0.05),血清NT-proBNP水平均低于本组治疗前(P<0.05),6MWD水平明显高于本组治疗前(P<0.05)。治疗后,试验组与对照组比较,上述各项血糖指标、心功能指标、运动耐力等的改善效果均更显著(P<0.05)。治疗期间两组患者出现的不良反应有胸闷、心慌、皮疹和胃肠道轻微不适等,均未出现明显不适和过敏情况,两组不良反应总发生率比较,差异不显著(P>0.05)。结论YQFM联合酒石酸美托洛尔治疗T2DM合并HF患者能发挥协同治疗作用,可显著改善患者心功能、提高运动耐量,且安全性好。
